Should I Buy AstraZeneca Plc?

Harvey Jones asks whether AstraZeneca plc (LON: AZN) is still bad medicine.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m shopping for shares again, should I pop AstraZeneca (LSE: AZN) (NYSE: AZN.US) into my basket?

The drugs don’t work

If you’re looking for a solid, defensive FTSE 100 stalwart, then look away now, because AstraZeneca isn’t it. The pharmaceutical giant has spent years trying to remedy expiring patents and a failing drugs pipeline, with mixed results. Broker forecasts are dismal, ranging from ‘underperform’, to ‘neutral’, to ‘hold’. Should I buck the trend and buy it?

Last time I looked at AstraZeneca, in October, I wrote that its share price had gone nowhere, slowly, for years. Patents were running out, its pipeline of replacement drugs was blocked, and management had resorted to sacking nearly 10% of its staff to shed weight. Since then, the share price has recovered a modest 9% to £33.07, although the FTSE 100 rose more than 13% over the same period. The longer-term share price story is uglier, with just 1% growth in three years against 22% for the FTSE 100 and an impressive 51% for arch rival GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

Profits plunge

AstraZeneca’s Q1 results piled on the misery, with a 13% fall in group revenue to £6.38bn, as it lost exclusivity for key drugs, and a 36% drop in pre-tax profits to $1.3bn. It wasn’t all bad news. Like many FTSE 100 companies, AstraZeneca is having more joy further afield, with sales rising 9% in emerging markets. It boasts 84 products in its drugs pipeline, and recently struck a deal with Amgen, the world’s largest biotechnology company, to develop five biotech drugs. AstraZeneca publishes its Q2 results on Thursday, when the market will be looking to see when its drugs pipeline will wash into the market.

I did like one thing about AstraZeneca: its yield. That was 6.1% in October and remains a peppy 5.6%, covered 2.3 times, easily beating GlaxoSmithKline’s 4.4% yield. There was something else to like, AstraZeneca’s lowly valuation of just 7.8 times earnings, which is almost half Glaxo’s current price-to-earnings ratio of 15 times earnings. So AstraZeneca is either an opportunity, or a great big flashing warning signal. Which is it?

Five better options

Forecast earnings per share (EPS) growth of -19% this calendar year -5% in 2014 suggests the latter. Chief executive Pascal Soriot faces a battle to get this company back into gear, as governments across the West look to contain spiralling drugs budgets. His attempts could stall if AstraZeneca gets sucked into the Chinese bribery scandal, in the wake of GlaxoSmithKlein. The company denies any wrongdoing, but the Chinese authorities are sniffing menacingly. We’ll learn more about AstraZeneca’s prospects on Thursday, but for now, the only compelling reason to buy it is the yield. Mind you, 5.6% is quite compelling.

If you’re looking for a rock solid share to retire on, AstraZeneca isn’t it. You can discover far better stocks in our special report 5 Shares To Retire On. This free report by Motley Fool share analysts names five FTSE 100 favourites to secure your retirement. To find out more, download this report now. It won’t cost you a penny, so click here.

> Harvey owns shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Should I follow Warren Buffett and sell my favourite shares?

Billionaire US investor Warren Buffett has been selling tons of Apple shares and other stocks of businesses he thinks are…

Read more »